Bridging the Gap: Sustained Treatment Effect of Glabellar Lines With Twice-A-Year Treatment With DaxibotulinumtoxinA

por Dover, Jeffrey S., Solish, Nowell, Gross, Todd M., Gallagher, Conor J., Brown, Jessica
Publicado 2023

Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A

por Solish, Nowell, Carruthers, Jean, Kaufman, Joely, Rubio, Roman G., Gross, Todd M., Gallagher, Conor J.
Publicado 2021

Treatment of Upper Facial Lines With DaxibotulinumtoxinA for Injection: Results From an Open-Label Phase 2 Study

por Dover, Jeffrey S., Humphrey, Shannon D., Lorenc, Z. Paul, Shamban, Ava, Gross, Todd M., Rubio, Roman G., Vitarella, Domenico
Publicado 2023

DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Efficacy Results From SAKURA 3, a Large, Open-Label, Phase 3 Safety Study

por Fabi, Sabrina G., Cohen, Joel L., Green, Lawrence J., Dhawan, Sunil, Kontis, Theda C., Baumann, Leslie, Gross, Todd M., Gallagher, Conor J., Brown, Jessica, Rubio, Roman G.
Publicado 2021

Efficacy and Safety of ATX-101 by Treatment Session: Pooled Analysis of Data From the Phase 3 REFINE Trials

por Dayan, Steven H, Schlessinger, Joel, Beer, Kenneth, Donofrio, Lisa M, Jones, Derek H, Humphrey, Shannon, Carruthers, Jean, Lizzul, Paul F, Gross, Todd M, Beddingfield, Frederick C, Somogyi, Christine
Publicado 2018